Novel lipophilic amidate oxorhenium and oxotechnetium complexes as potential brain agents: synthesis, characterization and biological evaluation.
Novel oxorhenium and oxotechnetium complexes based on the tetradentate 1-(2-hydroxybenzamido)-2-(pyridinecarboxamido)benzene, H3L, ligand have been synthesized and characterized herein. Thus, by reacting equimolar quantities of the triply deprotonated ligand L3- with the suitable MO3+ precursor, the following neutral MOL complexes could be easily produced following similar synthetic routes: M = Re (1), M = 99gTc (2), and M = 99mTc (3). Complexes 1 and 2, prepared in macroscopic amounts, were chemically characterized and their structure determined by single-crystal X-ray analysis. They are isostructural metal chelates, adopting a distorted square pyramidal geometry around the metal. The N3O donor atom set of the tetradentate ligand defines the basal plane and the oxygen atom of the M = O core occupies the apex of the pyramid. Complex 3 forms quantitatively at tracer level by mixing the H3L ligand with Na99mTcO4 generator eluate in aqueous alkaline media and using tin chloride as reductant in the presence of citrate. Its structure was established by chromatographic comparison with prototypic complexes 1 and 2 using high-performance liquid chromatographic techniques. When challenged with excess glutathione in vitro, complex 3 is rapidly converted to hydrophilic unidentified metal species. Tissue distribution data after administration of complex 3 in vivo revealed a significant uptake and retention of this compound in brain tissue.
Papadopoulos
M
M
Institute of Radioisotopes, National Centre for Scientific Research, Demokritos, Athens, Greece.
Nock
B
B
Maina
T
T
Pirmettis
I
I
Raptopoulou
C
C
Tasiopoulos
A
A
Troganis
A
A
Kabanos
T
T
Terzis
A
A
Chiotellis
E
E
D000818:Animals; D001921:Brain / Q000378:metabolism*; D018360:Crystallography, X-Ray; D004355:Drug Stability; D005978:Glutathione / Q000737:chemistry; D008297:Male; D051379:Mice; D009942:Organometallic Compounds / Q000138:chemical synthesis / Q000493:pharmacokinetics*; D015609:Organotechnetium Compounds / Q000138:chemical synthesis / Q000493:pharmacokinetics*; D010084:Oxidation-Reduction; D019275:Radiopharmaceuticals / Q000138:chemical synthesis* / Q000493:pharmacokinetics; D012211:Rhenium / Q000737:chemistry*; D014018:Tissue Distribution
D009942:Organometallic Compounds; D015609:Organotechnetium Compounds; D019275:Radiopharmaceuticals; D012211:Rhenium; D005978:Glutathione